Product Details:
Minimum Order Quantity | 10 Piece |
Prescription/Non prescription | Prescription |
Country of Origin | Made in India |
Strength | 3000 IU |
Product Details:
Minimum Order Quantity | 10 Piece |
Strength | 3000 IU |
Prescription/Non prescription | Prescription |
Country of Origin | Made in India |
Product Details:
Minimum Order Quantity | 10 Box |
Strength | 100 mg |
Packaging Size | 4 Capsules |
Also gives | PCD Pharma |
Form | Capsule |
Product Details:
Minimum Order Quantity | 10 Bottle |
Packaging Size | 30 Tablets |
Brand | Viraday |
Manufacturer | Cipla |
Composition | EFAVIRENZ-600MG + EMTRICITABINE-200MG + TENOFOVIR DISOPROXIL-300MG |
Packaging | Bottle of 30 Tablets |
Viraday Tablet belongs to the class of medicines called ‘antiretroviral agents’ used to treat HIV infection. HIV is a virus that attacks the immune cells of the body leading to decreased immunity. It spreads through body fluids such as semen, vaginal fluid, and blood. Symptoms include fever, chills, rash, night sweats, muscle aches, tiredness, and sore throat that usually last for days to several weeks.
Viraday Tablet contains Efavirenz, Emtricitabine, and Tenofovir. Efavirenz is a non-nucleoside reverse transcriptase inhibitor, whereas Emtricitabine and Tenofovir are nucleotide reverse transcriptase inhibitors. They work by inhibiting the reverse transcriptase enzyme production, which the HIV-infected cells must make to make new viruses. This effect helps to inhibit viral replication.
Additional Information:
Product Details:
Minimum Order Quantity | 10 Bottle |
Packaging Size | 30 Tablets |
Composition | Emtricitabine (200mg) + Tenofovir disoproxil fumarate (300mg) + Efavirenz (600mg) |
Treatment | HIV |
Prescription/Non prescription | Prescription |
Brand | Viraday |
Manufacturer | Cipla |
Form | Tablet |
Shelf life | 1Year |
Country of Origin | Made in India |
Viraday tablets are a medication used for the treatment of Human Immunodeficiency Virus (HIV) infection in adults. This combination drug contains three active ingredients: efavirenz, emtricitabine, and tenofovir disoproxil fumarate. Viraday is classified as an antiretroviral therapy (ART) and belongs to the category of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs).
Key Features:
HIV Treatment: Viraday is specifically formulated to suppress the replication of HIV in the body and reduce the viral load, thereby slowing down the progression of the disease and improving the patient's immune system.
Three-in-One Combination: This medication contains a combination of three active drugs, which work synergistically to target different stages of the HIV replication process. The three drugs are efavirenz, emtricitabine, and tenofovir disoproxil fumarate.
Once-Daily Dosage: Viraday is typically taken as a single tablet once daily. This convenience enhances medication adherence and increases the effectiveness of the treatment.
Prescribed for Adults: Viraday is approved for use in adults aged 18 years and older. It is not recommended for children or adolescents.
Prescription Only: Viraday is a prescription medication, and patients should only take it under the supervision of a qualified healthcare professional experienced in HIV treatment.
Precautions and Warnings:
Viraday is not a cure for HIV but is effective in controlling the virus. Patients must continue taking the medication as prescribed, even if they feel well, to maintain viral suppression.
Some individuals may experience side effects when starting Viraday treatment, such as dizziness, drowsiness, nausea, rash, or vivid dreams. Most side effects are temporary and tend to improve over time. Patients should report any persistent or severe side effects to their healthcare provider.
Prior to starting Viraday, patients should undergo HIV drug resistance testing to ensure the effectiveness of the medication against their particular strain of the virus.
Viraday may interact with certain medications, including other HIV drugs and medications metabolized by the liver. It is essential to inform the healthcare provider about all other medications being taken to avoid potential drug interactions.
Patients with pre-existing medical conditions, such as liver or kidney problems, should be closely monitored while taking Viraday.
Viraday may not be suitable for pregnant or breastfeeding individuals, and alternative HIV treatment options should be discussed with the healthcare provider.
This product description is for informational purposes only and does not replace professional medical advice. Patients should always consult their healthcare provider for personalized guidance on HIV treatment, potential side effects, and drug interactions. It is crucial to follow the prescribed dosage and recommendations for optimal treatment outcomes.